强生在宾夕法尼亚州投资10亿美元建设新细胞疗法基地。
J&J pours $1B into new cell therapy site in Pennsylvania
生命科学资讯
生物技术与制药领域的最新动态
查尔斯河公司强调，随着关税不确定性消退，需求增长显著。
Charles River highlights increase in demand as tariff uncertainties fade
更新：诺华与Unnatural Products签署大环化合物合作协议
Updated: Novartis signs macrocyclic deal with Unnatural Products
诺华与Unnatural Products签署大环化合物协议，预付款达1亿美元。
Novartis signs macrocyclic deal with Unnatural Products for $100M upfront
Moderna流感疫苗申请在FDA经历非典型路径后出现逆转。
Reversal on Moderna's flu application follows atypical path through FDA
礼来Zepbound与Taltz联合疗法公布银屑病与减重数据；诺华强化Rhapsido疗效结果。
Lilly's Zepbound, Taltz combo data in psoriasis and weight loss; Novartis bolsters Rhapsido results
Faeth与Sensei合并上市，通过股票销售净赚2亿美元
Faeth goes public in merger with Sensei, nets $200M in stock sale
FDA转变立场，将审查莫德纳流感疫苗。
FDA reverses course, will review Moderna’s flu vaccine
礼来以1亿美元预付款获得CSL的IL-6免疫炎症抗体许可。
Lilly licenses CSL’s IL-6 immuno-inflammatory antibody for $100M upfront
Paragon新生物技术公司Korsana挑战阿尔茨海默病，与罗氏一较高下。
Paragon's new biotech Korsana tackles Alzheimer's like Roche
Paragon最新生物技术将尝试像罗氏一样延缓阿尔茨海默病进程——Endpoints新闻
Paragon's latest biotech will try to slow Alzheimer's like Roche - Endpoints News
利奥制药宣布七年来首次实现盈利。
Leo Pharma says it's turned a profit for the first time in seven years
Moderna在Arbutus的mRNA专利战中遭遇挫折。
Moderna faces setback in Arbutus' mRNA patent fight
解锁健康数据
Unlocking health data
FDA拒绝Disc Medicine罕见病药物，尽管已授予其专员凭证。
FDA rejects Disc Medicine's rare disease drug despite granting it a commissioner voucher
六家生物科技公司递交港交所上市申请；法拉第制药公司关闭运营
Six biotechs file for HKEX listing; Faraday Pharmaceuticals shutters
康帕斯通路公司因第二阶段抑郁症治疗突破股价飙升
Compass Pathways soars on second Phase 3 depression hit
Ocular Therapeutix公司Axpaxli疗效优于Eylea，股价应声下跌。
Ocular Therapeutix’ Axpaxli shows superiority over Eylea, shares sink
勃林格殷格翰停止吸入式囊性纤维化基因疗法研发。
Boehringer Ingelheim stops work on inhaled cystic fibrosis gene therapy
Moderna与FDA之争；赛诺菲CEO保罗·哈德森离职；临床试验为何如此昂贵；及其他动态
Moderna vs FDA; Paul Hudson out at Sanofi; Why clinical trials are so costly; and more